ER+Ve Breast Cancer by Shyam Aggarwal
Session 7 : ER+Ve Breast Cancer
Chairpersons :
Hemant Malhotra, Gurpreet Singh
Speaker :
Shyam Aggarwal
BELLE-3 Trial of Buparlisib Plus Endocrine Therapy Meets Primary Endpoint of Progression Free Survival in Breast Cancer Patients
Author: Di Leo A
Conference: 2016 SABCS S4-07
The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action
Author: Friedman LS
Conference: 2016 SABCS S6-04
A randomized adaptive phase II/III study of buparlisib, a pan-Class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)
Author: M. Martin
Reference: Ann Oncol. 2016 Nov 14
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo controlled, phase II randomised PEGGY study
Author: P. Vuylsteke
Reference: Ann Oncol. 2016 Nov 1. pii: mdw562